Publication Name	World Journal of Clinical Oncology
Manuscript ID	107009
Country	China

Received	2025-03-14 06:49
Peer-Review Started	2025-03-14 06:49
To Make the First Decision
Return for Revision	2025-04-23 11:49
Revised	2025-05-07 16:26
Second Decision	2025-06-25 02:46
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-06-26 04:18
Articles in Press	2025-06-26 04:18
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-08-07 02:46
Publish the Manuscript Online	2025-08-20 08:41

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Retrospective Study
Article Title	Survival benefits of concurrent immune checkpoint inhibitor and radiotherapy in non-small cell lung cancer with brain metastases
Manuscript Source	Invited Manuscript
All Author List	Xue-Jie Liu, Heng Ge and Chun-Luan Yuan
ORCID	Author(s) ORCID Number Heng Ge http://orcid.org/0000-0003-4270-2556
Funding Agency and Grant Number
Corresponding Author	Chun-Luan Yuan, Department of Oncology, The First People’s Hospital of Lianyungang, No. 6 Zhenhua Road, Lianyungang 222016, Jiangsu Province, China. zhaoqin0909@sina.com
Key Words	Non-small cell lung cancer; Brain metastasis; Immune checkpoint inhibitor; Radiotherapy; Survival; Sequence
Core Tip	Immunotherapy can combine with radiotherapy to destroy cancer, either use radiotherapy and immunotherapy at the same time, or treated with radiotherapy first and then use immunotherapy. However, what is the better sequence of radiotherapy and immunotherapy for non-small cell lung cancer patients with brain metastasis? In the present study, we collected the data of non-small cell lung cancer patients with brain metastasis, we found some patients received radiotherapy at first, and then treated with immunotherapy. Those patients did not live as long as patients treated with radiotherapy and immunotherapy at the same time.
Publish Date	2025-08-20 08:41
Citation	<p>Liu XJ, Ge H, Yuan CL. Survival benefits of concurrent immune checkpoint inhibitor and radiotherapy in non-small cell lung cancer with brain metastases. <i>World J Clin Oncol</i> 2025; 16(8): 107009</p>
URL	https://www.wjgnet.com/2218-4333/full/v16/i8/107009.htm
DOI	https://dx.doi.org/10.5306/wjco.v16.i8.107009

Full Article (PDF)	WJCO-16-107009-with-cover.pdf
Manuscript File	107009_Auto_Edited_023356.docx
Answering Reviewers	107009-answering-reviewers.pdf
Audio Core Tip	107009-audio.wav
Biostatistics Review Certificate	107009-biostatistics-statement.pdf
Conflict-of-Interest Disclosure Form	107009-conflict-of-interest-statement.pdf
Copyright License Agreement	107009-copyright-assignment.pdf
Signed Informed Consent Form(s) or Document(s)	107009-informed-consent-statement.pdf
Institutional Review Board Approval Form or Document	107009-institutional-review-board-statement.pdf
Non-Native Speakers of English Editing Certificate	107009-non-native-speakers.pdf
Peer-review Report	107009-peer-reviews.pdf
Scientific Misconduct Check	107009-scientific-misconduct-check.png
Scientific Editor Work List	107009-scientific-editor-work-list.pdf
CrossCheck Report	107009-crosscheck-report.pdf